Pearce IP BioBlast w/e 26 Jan 2024
AbbVie announced it will invest US$233M in its biologics manufacturing facility in Singapore. The investment will add 24,000L of biologics…
Source: lexology.com
Genentech Lucentis News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Genentech Lucentis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Genentech Lucentis Today - Breaking & Trending Today
FDA Approves Yet Another Interchangeable Biosimilar and Another Biosimilar | McDonnell Boehnen Hulbert & Berghoff LLP
On October 3, 2023, the U.S. Food and Drug Administration (FDA) announced approval of Biogen's Byooviz (ranibizumab-nuna) as an interchangeable biosimilar to Genentech's Lucentis...
Source: jdsupra.com
BioBlast w/e 08 Dec 23
The FDA approved Vertex/CRISPR Therapeutics’ Casgevy® and Bluebird Bio’s Lyfgenia®, the first cell-based gene therapies to treat sickle cell disease…
Source: lexology.com
CVS Caremark Switches Up Biosimilar Coverage in 2024
As part of updates to its standard formulary, CVS Caremark has removed Amjevita and now prefers Hyrimoz and an unbranded biosimilar.
Source: ajmc.com
New Compound has Potential to Treat Wet AMD Without Injection
Animal studies of a new compound, which can be delivered by eye drop, have found that it can reverse epigenetic changes that lead to wet age-related macular degeneration.
Source: managedhealthcareexecutive.com